{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-25-000020","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.520329+00:00","generated_at":"2026-05-23T07:52:30.516451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised","bullets":["Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.","TAVR sales $1.05B (+3.8%, +5.4% constant currency); TMTT sales $115M (+58%).","Gross margin 78.7%; operating margin 27.9% (adj. 29.1%) on favorable mix and delayed expenses.","2025 guidance: total sales raised to $5.7-6.1B; TMTT raised to $530-550M; adj. EPS reaffirmed $2.40-2.50.","Q2 guidance: sales $1.45-1.53B, adj. EPS $0.59-0.65; CE Mark SAPIEN M3, NCD for EVOQUE."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-25-000020","json":"https://secwatch.observer/filing/0001099800-25-000020.json","markdown":"https://secwatch.observer/filing/0001099800-25-000020.md","text":"https://secwatch.observer/filing/0001099800-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/0001099800-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/ew-20250423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:52:30.516451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}